Virtual Nature Versus Guided Imagery for Anxiety and Well-Being in Hospitalized Older Adults
Bottom-Up Virtual Nature Versus Top-Down Guided Imagery in Hospitalized Older Adults: A Randomized Parallel-Group Clinical Trial
2 other identifiers
interventional
60
1 country
2
Brief Summary
Long hospital stays can be difficult for older adults. Being confined to a ward, with limited mobility and little access to the outdoors, may contribute to anxiety, low mood, and reduced well-being. Contact with nature is known to support relaxation and emotional recovery, but hospitalized patients often cannot go outside. This study compares two ways of bringing a nature experience to patients who are staying in hospital. In the first approach, participants wear a virtual reality headset and watch 360-degree videos filmed in real natural settings near Budapest: a meadow, a stream, and a mountain. The nature scene reaches them through their eyes and ears. In the second approach, participants listen to a short recorded audio guide and picture the same three nature scenes in their own minds, with their eyes closed. Here the nature scene is created by their own imagination. Both approaches use exactly the same nature themes. The only difference is how the experience reaches the person: from the outside through the senses, or from the inside through imagination. The study asks whether these two routes have different effects, and whether they can be told apart by measuring heart rate variability, which reflects how the body's automatic nervous system responds. Participants are adults aged 65 or older who have been in hospital for at least two weeks. After joining the study, each participant is first observed for two weeks while receiving only their usual hospital care. This period serves as their own comparison. They are then assigned by chance to one of the two approaches and take part in three sessions over two weeks. Questionnaires and brief cognitive tests are completed at three points: when joining, before the sessions begin, and after the sessions end. The main question is whether anxiety symptoms decrease more during the session period than during the preceding period of usual care. The study also looks at mood, attention and memory, well-being, and resilience.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable anxiety
Started Jun 2025
Typical duration for not_applicable anxiety
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2025
CompletedFirst Submitted
Initial submission to the registry
August 4, 2026
CompletedFirst Posted
Study publicly available on registry
August 14, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 1, 2027
August 14, 2026
August 1, 2026
1.6 years
August 4, 2026
August 10, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Change in anxiety symptoms (HADS-A)
Anxiety symptoms measured with the anxiety subscale of the Hospital Anxiety and Depression Scale (HADS-A). Scores range from 0 to 21; lower scores indicate less anxiety. The primary comparison is the change during the intervention period (T1 to T2) relative to the change during the preceding usual care observation period (T0 to T1), with each participant serving as their own control.
Baseline, Week 2, and Week 4
Heart rate variability during intervention sessions (RMSSD)
Root mean square of successive differences (RMSSD) recorded during intervention sessions with an optical photoplethysmographic armband sensor and analysed with dedicated heart rate variability software. RMSSD is computed from a five-minute artifact-free window in both arms and expressed in milliseconds; higher values indicate greater parasympathetic activity. Recordings with more than 5 percent corrected beats are excluded.
Week 2 through Week 4
Secondary Outcomes (9)
Change in depressive symptoms (HADS-D)
Baseline, Week 2, and Week 4
Change in depressive symptoms (GDS-15)
Baseline, Week 2, and Week 4
Change in global cognitive performance (MoCA)
Baseline, Week 2, and Week 4
Change in memory index (MoCA-MIS)
Baseline, Week 2, and Week 4
Change in attentional performance (MoCA attention subscale)
Baseline, Week 2, and Week 4
- +4 more secondary outcomes
Other Outcomes (3)
Affective state before intervention sessions (Emotion Thermometers)
Week 2 through Week 4
Immersive tendency (ITQ-10)
Baseline
Virtual reality sickness symptoms (VRSQ)
Week 2
Study Arms (2)
Immersive virtual reality nature exposure
EXPERIMENTALParticipants view 360-degree nature videos through a head-mounted display in a seated or semi-seated position. The videos were produced by the research team from a fixed tripod perspective at three locations near Budapest, corresponding to the three standardized motifs (meadow, stream, mountain). They contain no narration or added music, only the natural soundscape of the location. The viewpoint changes every five minutes. Exposure length ranges from 8 to 20 minutes according to participant tolerance. Three sessions are delivered over two weeks.
Guided imagery
ACTIVE COMPARATORParticipants listen through headphones, in a seated or semi-seated position with eyes closed, to a standardized five-minute audio recording that begins with a brief breathing relaxation followed by the motif text. The motifs are identical to those presented in the virtual reality arm (meadow, stream, mountain). After the session, participants give a free verbal account of their experience. Three sessions are delivered over two weeks.
Interventions
Three sessions of 360-degree nature video viewed through a head-mounted display, delivered over two weeks. Videos were produced by the research team from a fixed tripod perspective at three locations near Budapest, corresponding to the motifs of meadow, stream, and mountain. They contain no narration or added music, only the natural soundscape of the location, and the viewpoint changes every five minutes. Exposure length ranges from 8 to 20 minutes according to participant tolerance. Sessions are conducted at the bedside under supervision, with the device used offline.
Three sessions of guided imagery delivered over two weeks. Participants listen through headphones, with eyes closed, to a standardized five-minute audio recording that begins with a brief breathing relaxation followed by the motif text. The motifs are identical to those presented in the virtual reality arm and are drawn from the motif repertoire of Katathym Imaginative Psychotherapy. After each session, participants give a free verbal account of their experience.
Eligibility Criteria
You may qualify if:
- Aged 65 years or older
- Receiving inpatient hospital care, with at least two weeks of hospitalisation at the time of enrolment
- Montreal Cognitive Assessment (Hungarian version) score of 18 or above, with education correction
- Physically able to safely wear a head-mounted virtual reality display
- Adequate corrected or uncorrected vision and hearing
- Able to communicate in Hungarian
- Stable psychiatric and cardiovascular condition, as determined from medical history and in consultation with the treating physician
- Able to provide independent written informed consent
You may not qualify if:
- Epilepsy with recurrent seizures, or photosensitivity
- Neurological condition associated with increased risk during virtual reality use, including Meniere's disease and significant carotid stenosis
- Active psychosis, hallucinations, or severe depression with psychotic features
- Open wound or skin lesion on the face, chronic neck pain, or spinal condition preventing safe use of the head-mounted display
- Severe uncorrectable sensory impairment
- Unstable psychotropic medication during the preceding eight weeks
- Regular use of analgesic or psychotropic medication that may substantially affect perception of the experience
- Active alcohol or substance use disorder within the past year
- Refusal or inability to provide informed consent
- Enrolment is deferred, rather than excluded, in the presence of active delirium or infectious illness, until the condition resolves.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Semmelweis University, Department of Geriatrics and Nursing Science
Budapest, 1097, Hungary
Semmelweis University, Department of Rehabilitation Medicine
Budapest, 1121, Hungary
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Xenia Gonda, MA, PharmD, PhD
Semmelweis University, Department of Psychiatry and Psychotherapy
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Masking Details
- Neither participants nor facilitators can be masked given the nature of the interventions. Outcome assessments are conducted by ward clinical psychologists who may learn the allocation through routine patient contact; assessor masking is therefore not claimed. Heart rate variability data are processed using predefined automated parameters without knowledge of group allocation.
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 4, 2026
First Posted
August 14, 2026
Study Start
June 1, 2025
Primary Completion (Estimated)
January 1, 2027
Study Completion (Estimated)
January 1, 2027
Last Updated
August 14, 2026
Record last verified: 2026-08
Data Sharing
- IPD Sharing
- Will not share
Individual participant data will not be shared publicly. The dataset contains detailed clinical, medication, and laboratory information collected from a small sample of hospitalised older adults at two clinical departments, and the combination of these variables would create a re-identification risk that pseudonymisation alone cannot adequately address. Aggregated and anonymised results will be reported in peer-reviewed publications. Requests for access to specific data supporting the published findings may be directed to the corresponding author and will be considered on a case-by-case basis, subject to institutional and ethical approval.